Draft:Medtide

  • Comment: Primary sources and routine business reporting do not establish notability per WP:NCORP. DoubleGrazing (talk) 07:40, 15 November 2025 (UTC)
Medtide Inc.
Native name
泰德医药（浙江）股份有限公司
Company type
Public
SEHK: 3880
IndustryBiotechnology
HeadquartersHangzhou, Zhejiang, China
ProductsPeptide and peptide-related active pharmaceutical ingredients
ServicesContract research, development and manufacturing services
SubsidiariesCPC Scientific Inc.
Websitewww.medtideinc.com/en/

Medtide Inc. (Chinese: 泰德医药（浙江）股份有限公司) is a peptide- and oligonucleotide-focused contract research, development and manufacturing organization (CRDMO) headquartered in Hangzhou, Zhejiang, China.[1][2] Independent industry analysis has ranked Medtide among the largest peptide-focused CRDMO providers globally, with reporting by 36Kr identifying the company as the third-largest peptide CRDMO worldwide by 2023 sales revenue.[3]

The company provides full-cycle services from early-stage discovery and pre-clinical research to clinical development and commercial-stage production of active pharmaceutical ingredients (APIs).[1][4]

History

Medtide launched an initial public offering (IPO) on the Main Board of the Hong Kong Stock Exchange in June 2025, offering H shares under stock code 3880.HK.[5][6] The listing was underwritten by a syndicate led by Morgan Stanley Asia Limited and CITIC Securities (Hong Kong) Limited.[2] Gross proceeds from the global offering were reported at approximately HK$411 million.[5]

Financial and industry media noted that the IPO was intended to fund expansion of Medtide’s peptide production capacity and international footprint, including projects related to peptide drugs for metabolic and weight-management indications.[7][8] Coverage of the company’s trading debut described Medtide as a peptide-focused CRDMO and reported modest gains in early trading.[9]

Business

Medtide’s business model combines contract research organization (CRO) and contract development and manufacturing organization (CDMO) services for peptide-based therapeutics.[4][10] Its CRO activities focus on peptide new chemical entity (NCE) discovery and synthesis, while its CDMO services cover peptide chemistry, manufacturing and controls (CMC) development and commercial-scale manufacturing of peptide and oligonucleotide drug products.[4][10]

The company states that it primarily supplies peptide and oligonucleotide drug products rather than finished dosage forms, with customers using its APIs in the development and commercialization of peptide drugs in multiple therapeutic areas.[4] Medtide reports commercial production bases and offices in both China and the United States and provides services to pharmaceutical and biotechnology companies in more than 50 countries.[1]

Industry and financial analyses highlight Medtide’s strategic focus on the high-growth market for glucagon-like peptide-1 (GLP-1) and related peptide therapies and describe the company as one of the larger peptide- and oligonucleotide-focused CRDMO providers globally.[3][11][12]

Subsidiaries

Medtide is the parent company of CPC Scientific Inc., a contract research, development and manufacturing organization specializing in peptides and oligonucleotides. CPC Scientific is described in industry sources as a subsidiary of Medtide and as part of the group’s global CRDMO platform.[13][14]

See also

References

  1. ^ a b c "Medtide Inc. – About Us". Medtide Inc. Retrieved 14 November 2025.
  2. ^ a b "Herbert Smith Freehills Kramer advises underwriters of Medtide's Hong Kong IPO". Mondaq. Herbert Smith Freehills Kramer. 1 July 2025. Retrieved 14 November 2025.
  3. ^ a b "Listed Company in Qiantang, Hangzhou, the World's Third-Largest Peptide CRDMO". 36Kr. 3 July 2025. Retrieved 17 November 2025.
  4. ^ a b c d "Medtide Inc. – Interim Results Announcement" (PDF). HKEXnews. Hong Kong Exchanges and Clearing. 29 August 2025. Retrieved 14 November 2025.
  5. ^ a b "Medtide HK$411.2 million IPO". Davis Polk. Davis Polk & Wardwell LLP. 2 July 2025. Retrieved 14 November 2025.
  6. ^ "Peptide CRDMO rising star launches HK IPO". SeniorPharma. Retrieved 14 November 2025.
  7. ^ "Medtide launches IPO to bulk up its weight-loss business". The Bamboo Works. 26 June 2025. Retrieved 14 November 2025.
  8. ^ "Medtide Inc. Eyes Major Funds In Hong Kong IPO". Finimize. June 2025. Retrieved 14 November 2025.
  9. ^ "BRIEF: Medtide rises in Hong Kong trading debut". The Bamboo Works. 30 June 2025. Retrieved 14 November 2025.
  10. ^ a b "IPO – Company Information: Medtide Inc. (03880)". ET Net. Retrieved 14 November 2025.
  11. ^ "Medtide ranked as the world's third-largest peptide-focused CRDMO with 1.5% market share". Tiger Brokers / Itiger. 2025. Retrieved 17 November 2025.
  12. ^ "Medtide – IPOX". IPOX. 30 June 2025. Retrieved 14 November 2025.
  13. ^ "About CPC Scientific Inc". CPhI Online. Retrieved 14 November 2025.
  14. ^ "Warm Congratulations to MEDTIDE INC. on its successful listing on the Hong Kong Stock Exchange!". CPC Scientific. 30 June 2025. Retrieved 14 November 2025.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.